Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;45(4):639-652.
doi: 10.1016/j.gtc.2016.07.003. Epub 2016 Oct 13.

Nonalcoholic Fatty Liver Disease: Pathophysiology and Management

Rotonya M Carr  1 , Amanke Oranu  2 , Vandana Khungar  2
Affiliations
Review

Nonalcoholic Fatty Liver Disease: Pathophysiology and Management

Rotonya M Carr et al. Gastroenterol Clin North Am. 2016 Dec.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an important cause of morbidity and mortality worldwide and is rapidly becoming the leading cause of end-stage liver disease and liver transplant. With a prevalence of 30% in the United States, it has reached epidemic proportions. The clinical syndrome of NAFLD spans from bland steatosis to steatohepatitis, which can progress to fibrosis and cirrhosis. The pathogenesis includes the roles of hormones, nutritional and intestinal dysbiosis, insulin resistance, lipotoxicity, hepatic inflammation, and genes. Noninvasive testing and liver biopsy indications are reviewed. Approved and investigational therapies for NAFLD and nonalcoholic steatohepatitis are outlined in this article.

Keywords: Hepatic steatosis; Lipid droplet; NASH; NASH therapeutics; Nonalcoholic fatty liver disease; Obesity; Perilipins.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pathogenesis of NAFLD.
Figure 2
Figure 2
Strategies to reduce cardiovascular, oncologic and hepatic mortality in NAFLD patients. Rx=pharmacologic
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology. 2012;55:2005–2023. - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2015 - PubMed
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. - PubMed
    1. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in asian-indian men. Proc Natl Acad Sci U S A. 2006;103:18273–18277. - PMC - PubMed
    1. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274–283. - PMC - PubMed

Publication types

MeSH terms

Substances